Trial intelligence / Profile preview

Topical 2% Tofacitinib for Nail Psoriasis

NCT07313072Phase 2

Key facts

Status: Active, not recruiting
Start: Sep 2026
Primary completion: Apr 2027
Countries: 1
Sponsor: Hexsel Dermatology Clinic
Modality: Small Molecules

Drugs: INN-04-01
Conditions: nail psoriasis

Overview

Phase 2, open-label, single-arm trial of INN-04-01 in nail psoriasis, sponsored by Hexsel Dermatology Clinic. Primary endpoint: Efficacy of topical 2% tofacitinib at 26 weeks. Started Sep 2026; status: active, not recruiting.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Medicated Nail Lacquer
Participants receive one bottle of nail lacquer containing Tofacitinib 2% for home use, applied once daily to the affected nail(s) after removing the previous layer.

Who it enrols

Adults with nail psoriasis in at least one nail, not using systemic medication or without adequate response after 6 months. Excludes pregnant/breastfeeding women and those who initiated systemic medication <6 months prior.

Endpoints

Primary

Efficacy of topical 2% tofacitinib26 weeks

Secondary

Safety of 2% Tofacitinib26 weeks
Quality of Life26 weeks
Treatment Adherence with 2% Tofacitinib26 weeks

Beyond the preview

Go deeper on NCT07313072.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07313072.